Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James G Jackson

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Cancer Heterogeneity and Plasticity|February 6, 2026
The three barriers senescent tumor cells must overcome to relapseJames G Jackson
Oncotarget|February 16, 2017
TNBC invasion: downstream of STAT3James G Jackson, Guillermina Lozano
The EMBO Journal|September 11, 2012
Che-ating death: CHE1/AATF protects from p53-mediated apoptosisJames G Jackson, Guillermina Lozano
NPJ Precision Oncology|January 10, 2019
Analysis across multiple tumor types provides no evidence that mutant p53 exerts dominant negative activityAshkan Shahbandi, James G Jackson
Trends in Cancer|July 26, 2017
SASP: Tumor Suppressor or Promoter? Yes!Sonia G Rao, James G Jackson
Molecular & Cellular Oncology|January 30, 2020
Engulfment and cannibalism drive persistence of chemotherapy-treated tumor cells: can they be targeted?Crystal A Tonnessen-Murray, James G Jackson
Molecular and Cellular Biology|March 16, 2006
Primary and compensatory roles for RB family members at cell cycle gene promoters that are deacetylated and downregulated in doxorubicin-induced senescence of breast cancer cellsJames G Jackson, Olivia M Pereira-Smith
Cancer Research|September 5, 2006
p53 is preferentially recruited to the promoters of growth arrest genes p21 and GADD45 during replicative senescence of normal human fibroblastsJames G Jackson, Olivia M Pereira-Smith
The Journal of Pathology|October 20, 2010
Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivoJames G Jackson, Sean M Post, Guillermina Lozano
Trends in Cancer|February 17, 2020
TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the HeadlinesAshkan Shahbandi, Hoang D Nguyen, James G Jackson
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Cancer Heterogeneity and Plasticity|February 6, 2026
The three barriers senescent tumor cells must overcome to relapseJames G Jackson
Oncotarget|February 16, 2017
TNBC invasion: downstream of STAT3James G Jackson, Guillermina Lozano
The EMBO Journal|September 11, 2012
Che-ating death: CHE1/AATF protects from p53-mediated apoptosisJames G Jackson, Guillermina Lozano
NPJ Precision Oncology|January 10, 2019
Analysis across multiple tumor types provides no evidence that mutant p53 exerts dominant negative activityAshkan Shahbandi, James G Jackson
Trends in Cancer|July 26, 2017
SASP: Tumor Suppressor or Promoter? Yes!Sonia G Rao, James G Jackson
Molecular & Cellular Oncology|January 30, 2020
Engulfment and cannibalism drive persistence of chemotherapy-treated tumor cells: can they be targeted?Crystal A Tonnessen-Murray, James G Jackson
Molecular and Cellular Biology|March 16, 2006
Primary and compensatory roles for RB family members at cell cycle gene promoters that are deacetylated and downregulated in doxorubicin-induced senescence of breast cancer cellsJames G Jackson, Olivia M Pereira-Smith
Cancer Research|September 5, 2006
p53 is preferentially recruited to the promoters of growth arrest genes p21 and GADD45 during replicative senescence of normal human fibroblastsJames G Jackson, Olivia M Pereira-Smith
The Journal of Pathology|October 20, 2010
Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivoJames G Jackson, Sean M Post, Guillermina Lozano
Trends in Cancer|February 17, 2020
TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the HeadlinesAshkan Shahbandi, Hoang D Nguyen, James G Jackson
Pageof 4